Seagate Technology Holdings PLC vs 10X Genomics Inc — how do they compare? Seagate Technology Holdings PLC trades at $887 (market cap $205.65B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Seagate Technology Holdings PLC is far larger — about 24.1× 10X Genomics Inc's market cap, and Seagate Technology Holdings PLC pays a 0.33% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| STX | TXG | |
|---|---|---|
Market Cap | $205.65B | $8.55B |
Sector | Technology | Health |
52-Week High | $1.09K | $67.29 |
52-Week Low | $193.04 | $11.34 |
Enterprise Value | $207.80B | $8.08B |
Dividend Yield | 0.33% | — |
Signals from Pluang's Aura AI — not financial advice
Seagate Technology (STX) trades at $904.38, up 6.49% today, with strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with support at $868 and resistance at $933. Recent earnings beats and robust 2026 revenue guidance of $12.2B highlight fundamental strength, though valuation ratios remain elevated with P/E at 65.06. Analyst consensus is bullish with a $1,130 price target, supported by institutional accumulation and positive media coverage of HAMR technology adoption.
Outlook: STX benefits from AI-driven storage demand and operational execution, but faces risks from high debt and competitive pressures. The stock's premium valuation requires sustained growth to justify upside. Near-term catalysts include Q3 earnings and product ramps, while macroeconomic volatility and execution missteps pose headwinds. Investor sentiment remains positive, but caution is warranted given rich multiples.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Trailing returns across standard periods
Latest headlines on both assets
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →